index: hide

| Genetic Alteration (ie, Driver event) | Available Targeted Agents with Activity Against Driver Event in Lung Cancer |
|---------------------------------------|-----------------------------------------------------------------------------|
| High-level MET amplification or MET exon 14 skipping mutation | Crizotinib {'21623265},2,{'25971938},{'25971939},{'26729443} |
| RET rearrangements | Cabozantinib {'23533264},{'27825636} <br />Vandetanib {'27803005} |
| ERBB2 (HER2) mutations | Ado-trastuzumab emtansine {'29989854} |
| Tumor mutational burden (TMB)* | Nivolumab + ipilimumab {'29658845} <br />Nivolumab {'28636851} |

\* TMB is an evolving biomarker that may be helpful in selecting patients for immunotherapy. There is no consensus on how to measure TMB.